[Overexpression of the long non-coding RNA ADAMTS9-AS2 suppresses colorectal cancer proliferation and metastasis].
Journal
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
ISSN: 1672-7347
Titre abrégé: Zhong Nan Da Xue Xue Bao Yi Xue Ban
Pays: China
ID NLM: 101230586
Informations de publication
Date de publication:
28 Jul 2019
28 Jul 2019
Historique:
entrez:
16
8
2019
pubmed:
16
8
2019
medline:
24
8
2019
Statut:
ppublish
Résumé
To investigate the expression, clinical significance, and biological function of the long non-coding RNA (lncRNA) ADAMTS9-AS2 in colorectal cancer (CRC).
Methods: Gene microarray analysis was performed to explore the expression of ADAMTS9-AS2 in CRC. Real-time PCR was used to verify its expression in 20-paired CRC tissues and adjacent non-tumor tissues. We further explored the relationship between ADAMTS9-AS2 expression and clinicopathological features, and its prognostic role in relapse-free survival (RFS) among early stage CRC patients using Kaplan-Meier and Cox regression analyses. In vitro assays, cell counting kit-8 assay, colony formation assay, and Transwell assay were used to evaluate the biological function of ADAMTS9-AS2 in CRC.
Results: ADAMTS9-AS2 was down-regulated in CRC patients according to the gene microarray analysis, which was confirmed in CRC tissues and cells. High expression of ADAMTS9-AS2 was associated with a higher 5-year RFS rate (83.8% vs 73.5%, P=0.041) and it was an independent prognostic factor for RFS [hazard ratio (HR)=0.528; 95% CI 0.299 to 0.932; P=0.028] at the early stage of CRC. ADAMTS9-AS2 overexpression in CRC cells inhibited cell proliferation, migration, and invasion, while suppression of ADAMTS9-AS2 showed opposite effects.
Conclusion: ADAMTS9-AS2 is a valuable prognostic factor for CRC and may function as a tumor suppressor in CRC via inhibiting cell proliferation and metastasis. 目的:探讨长链非编码RNA(long non-coding RNA,lncRNA)ADAMTS9-AS2在结直肠癌(colorectal cancer,CRC)中的表达、临床意义和生物学作用。方法:利用基因芯片数据分析CRC中ADAMTS9-AS2的表达情况,并利用real-time PCR技术在20例CRC组织和癌旁正常组织及细胞系中进行验证。利用基因芯片提供的临床数据进行临床病理特征相关性分析、Kaplan-Meier生存分析和Cox回归分析。利用CCK-8、克隆形成和Transwell迁移和侵袭实验检测ADAMTS9-AS2对CRC细胞增殖、迁移和侵袭能力的影响。结果:ADAMTS9-AS2在CRC组织和细胞中显著低表达(P<0.05),其表达高低与早期CRC患者的年龄、性别、分期、病灶位置和错配修复状态均无明显相关性(P>0.05)。在早期CRC患者中,ADAMTS9-AS2高表达组患者的5年无复发生存率高于低表达组(83.8% vs 73.5%,P=0.041),ADAMTS9-AS2高表达是CRC患者无复发生存的独立保护因素(风险比=0.528,95% CI:0.299~0.932;P=0.028)。ADAMTS9-AS2表达上调能明显抑制CRC细胞的增殖和转移(P<0.05),表达下调则导致相反的结果(P<0.05)。结论:ADAMTS9-AS2通过抑制CRC细胞的增殖和转移发挥抑癌基因的作用,是CRC重要的预后因素。.
Autres résumés
Type: Publisher
(chi)
目的:探讨长链非编码RNA(long non-coding RNA,lncRNA)ADAMTS9-AS2在结直肠癌(colorectal cancer,CRC)中的表达、临床意义和生物学作用。方法:利用基因芯片数据分析CRC中ADAMTS9-AS2的表达情况,并利用real-time PCR技术在20例CRC组织和癌旁正常组织及细胞系中进行验证。利用基因芯片提供的临床数据进行临床病理特征相关性分析、Kaplan-Meier生存分析和Cox回归分析。利用CCK-8、克隆形成和Transwell迁移和侵袭实验检测ADAMTS9-AS2对CRC细胞增殖、迁移和侵袭能力的影响。结果:ADAMTS9-AS2在CRC组织和细胞中显著低表达(P<0.05),其表达高低与早期CRC患者的年龄、性别、分期、病灶位置和错配修复状态均无明显相关性(P>0.05)。在早期CRC患者中,ADAMTS9-AS2高表达组患者的5年无复发生存率高于低表达组(83.8% vs 73.5%,P=0.041),ADAMTS9-AS2高表达是CRC患者无复发生存的独立保护因素(风险比=0.528,95% CI:0.299~0.932;P=0.028)。ADAMTS9-AS2表达上调能明显抑制CRC细胞的增殖和转移(P<0.05),表达下调则导致相反的结果(P<0.05)。结论:ADAMTS9-AS2通过抑制CRC细胞的增殖和转移发挥抑癌基因的作用,是CRC重要的预后因素。.
Identifiants
pubmed: 31413211
doi: 10.11817/j.issn.1672-7347.2019.190142
doi:
Substances chimiques
RNA, Long Noncoding
0
ADAMTS9 Protein
EC 3.4.24.-
ADAMTS9 protein, human
EC 3.4.24.-
Types de publication
Journal Article
Langues
chi
Sous-ensembles de citation
IM